Clinical Trials

Phase 2 Not yet recruiting

Pancreatic Neoplasms

NCT07424664 2026-02-20

A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer

30 enrolled

Gynecologic

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

NCT05502237 2026-01-30

STAR-121

Phase 3 Active not recruiting

1,021 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05840224 2026-01-28

Study of GS-4528 in Adults With Solid Tumors

Phase 1 Active not recruiting

182 enrolled

Solid Tumor

NCT06048133 2026-01-23

Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)

33 enrolled

Phase 2 Not yet recruiting

Bile Duct Neoplasms, Cholangiocarcinoma

NCT07337447 2026-01-13

REWENEC 01

122 enrolled

Endocrine

Carcinoma, Neuroendocrine

NCT04656535 2026-01-07

AB154 Combined With AB122 for Recurrent Glioblastoma

Phase EARLY_PHASE1 Active not recruiting

46 enrolled

CNS

Glioblastoma, Recurrence

NCT05007782 2025-12-29

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

Phase 1 Recruiting

416 enrolled

Advanced Solid Tumor

NCT07283848 2025-12-26

Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma

Phase 2 Withdrawn

Phase 2 Active not recruiting

Stomach Neoplasms

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

Phase 1/2 Recruiting

31 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04854499 2025-11-19

ELEVATE HNSCC

Phase 2 Terminated

193 enrolled 27 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04791839 2025-11-05

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04660812 2025-10-20

ARC-9

Phase 1/2 Completed

227 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT05886634 2025-10-20

A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma

16 enrolled

Sarcoma

Liposarcoma, Sarcoma

NCT06790706 2025-10-06

IMMUNORARE5

EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

154 enrolled

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT06082960 2025-09-10

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Phase 1 Active not recruiting

45 enrolled

DermatologicGastrointestinalGynecologicLymphoidPlasma cellThoracic

Solid Tumors

NCT04772989 2025-08-28

ARC-12

Phase 1 Completed

94 enrolled

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Stomach Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT05024097 2025-08-27

PANTHER

43 enrolled

Phase 2 Active not recruiting

Rectal Neoplasms

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Phase 1/2 Completed

173 enrolled

Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05632848 2025-07-21

Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients

Phase 2 Completed

47 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05724563 2025-05-21

Domvanalimab and Zimberelimab in Advanced Liver Cancers

58 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms, Cholangiocarcinoma

NCT05915442 2025-05-20

SBRT-AMICO

23 enrolled

Genitourinary

Oligometastatic Prostate Cancer

NCT06532565 2025-05-16

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Phase 1 Recruiting

154 enrolled

Advanced Solid Tumors

NCT05177770 2025-05-08

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2 Terminated

16 enrolled 10 charts

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT05130177 2025-05-07

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma